C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease

被引:39
作者
Burger, Pascal M. [1 ]
Koudstaal, Stefan [2 ]
Mosterd, Arend [3 ]
Fiolet, Aernoud T. L. [4 ]
Teraa, Martin [5 ]
van der Meer, Manon G. [4 ]
Cramer, Maarten J. [4 ]
Visseren, Frank L. J. [1 ]
Ridker, Paul M. [6 ]
Dorresteijn, Jannick A. N. [1 ,7 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, Utrecht, Netherlands
[2] Green Heart Hosp, Dept Cardiol, Gouda, Netherlands
[3] Meander Med Ctr, Dept Cardiol, Amersfoort, Netherlands
[4] Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands
[6] Harvard Med Sch, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA USA
[7] Univ Med Ctr Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
关键词
atherosclerotic vascular disease; C-reactive protein; heart failure; inflammation; secondary prevention; INFLAMMATORY MARKERS; CYTOKINES;
D O I
10.1016/j.jacc.2023.05.035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Patients with established cardiovascular disease (CVD) are at high risk of incident heart failure (HF), which may in part reflect the impact of systemic inflammation.OBJECTIVES The goal of this study was to determine the association between C-reactive protein (CRP) and incident HF in patients with established CVD.METHODS Patients from the prospective UCC-SMART (Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease) cohort with established CVD, but without prevalent HF were included (n = 8,089). Incident HF was defined as a first hospitalization for HF. The association between baseline CRP and incident HF was assessed using Cox proportional hazards models adjusted for established risk factors (ie, age, sex, myocardial infarction, smoking, diabetes mellitus, body mass index, blood pressure, cholesterol, and kidney function).RESULTS During a median follow-up of 9.7 years (IQR 5.4-14.1 years), 810 incident HF cases were observed (incidence rate 1.01/100 person-years). Higher CRP was independently associated with an increased risk of incident HF: HR per 1 mg/L: 1.10 (95% CI: 1.07-1.13), and for last vs first CRP quartile: 2.22 (95% CI: 1.76-2.79). The association was significant for both HF with reduced (HR: 1.09; 95% CI: 1.04-1.14) and preserved ejection fraction (HR: 1.12; 95% CI: 1.07-1.18) (P for difference = 0.137). Additional adjustment for medication use and interim myocardial infarction did not attenuate the association, and the association remained consistent beyond 15 years after the CRP measurement.CONCLUSIONS In patients with established CVD, CRP is an independent risk marker of incident HF. These data support ongoing trial efforts to assess whether anti-inflammatory agents can reduce the burden of HF. (J Am Coll Cardiol 2023;82:414-426) & COPY; 2023 by the American College of Cardiology Foundation.
引用
收藏
页码:414 / 426
页数:13
相关论文
共 33 条
  • [1] Novel metabolic risk factors for incident heart failure and their relationship with obesity
    Bahrami, Hossein
    Bluemke, David A.
    Kronmal, Richard
    Bertoni, Alain G.
    Lloyd-Jones, Donald M.
    Shahar, Eyal
    Szklo, Moyses
    Lima, Joao A. C.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (18) : 1775 - 1783
  • [2] Cytokines as emerging targets in the treatment of heart failure
    Baumgarten, G
    Knuefermann, P
    Mann, DL
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (05) : 216 - 223
  • [3] White Blood Cell Count, C-Reactive Protein, and Incident Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study
    Bekwelem, Wobo
    Lutsey, Pamela L.
    Loehr, Laura R.
    Agarwal, Sunil K.
    Astor, Brad C.
    Guild, Cameron
    Ballantyne, Christie M.
    Folsom, Aaron R.
    [J]. ANNALS OF EPIDEMIOLOGY, 2011, 21 (10) : 739 - 748
  • [4] Role of cytokines in heart failure
    Blum, A
    Miller, H
    [J]. AMERICAN HEART JOURNAL, 1998, 135 (02) : 181 - 186
  • [5] Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
    Bonnet, F.
    Scheen, A. J.
    [J]. DIABETES & METABOLISM, 2018, 44 (06) : 457 - 464
  • [6] Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men
    Buddeke, J.
    Valstar, G. B.
    van Dis, I.
    Visseren, F. L. J.
    Rutten, F. H.
    den Ruijter, H. M.
    Vaartjes, I.
    Bots, M. L.
    [J]. BMC PUBLIC HEALTH, 2020, 20 (01)
  • [7] Cohort profile: the Utrecht Cardiovascular Cohort-Second Manifestations of Arterial Disease (UCC-SMART) Study-an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands
    Castelijns, Maria C.
    Helmink, Marga A. G.
    Hageman, Steven H. J.
    Asselbergs, Folkert W.
    de Borst, Gert J.
    Bots, Michiel L.
    Cramer, Maarten J.
    Dorresteijn, Jannick A. N.
    Emmelot-Vonk, Marielle H.
    Geerlings, Mirjam, I
    de Jong, Pim A.
    van der Kaaij, Niels P.
    Kappelle, L. Jaap
    Lely, A. Titia
    van der Meer, Manon G.
    Mol, Barend M.
    Nathoe, Hendrik M.
    Onland-Moret, N. Charlotte
    van Petersen, Rutger B.
    Ruigrok, Ynte M.
    van Smeden, Maarten
    Teraa, Martin
    Vandersteen, Angela
    Verhaar, Marianne C.
    Westerink, Jan
    Visseren, Frank L. J.
    [J]. BMJ OPEN, 2023, 13 (02):
  • [8] Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
    de Boer, Rudolf A.
    Nayor, Matthew
    deFilippi, Christopher R.
    Enserro, Danielle
    Bhambhani, Vijeta
    Kizer, Jorge R.
    Blaha, Michael J.
    Brouwers, Frank P.
    Cushman, Mary
    Lima, Joao A. C.
    Bahrami, Hossein
    van der Harst, Pim
    Wang, Thomas J.
    Gansevoort, Ron T.
    Fox, Caroline S.
    Gaggin, Hanna K.
    Kop, Willem J.
    Liu, Kiang
    Vasan, Ramachandran S.
    Psaty, Bruce M.
    Lee, Douglas S.
    Hillege, Hans L.
    Bartz, Traci M.
    Benjamin, Emelia J.
    Chan, Cheeling
    Allison, Matthew
    Gardin, Julius M.
    Januzzi, James L., Jr.
    Shah, Sanjiv J.
    Levy, Daniel
    Herrington, David M.
    Larson, Martin G.
    van Gilst, Wiek H.
    Gottdiener, John S.
    Bertoni, Alain G.
    Ho, Jennifer E.
    [J]. JAMA CARDIOLOGY, 2018, 3 (03) : 215 - 224
  • [9] The Evolving Role of C-Reactive Protein in Atherothrombosis
    Devaraj, Sridevi
    Singh, Uma
    Jialal, Ishwarlal
    [J]. CLINICAL CHEMISTRY, 2009, 55 (02) : 229 - 238
  • [10] Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
    Everett, Brendan M.
    Cornel, Jan H.
    Lainscak, Mitja
    Anker, Stefan D.
    Abbate, Antonio
    Thuren, Tom
    Libby, Peter
    Glynn, Robert J.
    Ridker, Paul M.
    [J]. CIRCULATION, 2019, 139 (10) : 1289 - 1299